Lu Si Selected Research

Sunitinib (Sutent)

5/2016	Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.
5/2015	[A pilot study of sunitinib as first-line therapy for metastatic renal cell carcinoma on a 2 weeks on/1 week off intermittent dosing schedule].
10/2014	[Genetic polymorphisms of PDGFR associated with thrombocytopenia in Chinese patients with clear-cell metastatic renal cell carcinoma treated with sunitinib].

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lu Si Research Topics

Disease

93	Melanoma (Melanoma, Malignant) 06/2024 - 08/2008
30	Neoplasms (Cancer) 05/2024 - 05/2014
13	Neoplasm Metastasis (Metastasis) 01/2024 - 08/2008
13	Disease Progression 01/2023 - 07/2011
10	Renal Cell Carcinoma (Grawitz Tumor) 01/2022 - 11/2012
4	Breast Neoplasms (Breast Cancer) 01/2021 - 07/2014
3	Diarrhea 01/2023 - 05/2018
3	Carcinoma (Carcinomatosis) 01/2023 - 05/2016
3	Lymphatic Metastasis 01/2021 - 12/2013
2	Vomiting 01/2023 - 11/2012
2	Proteinuria 01/2023 - 05/2020
2	Leukopenia 01/2023 - 05/2020
2	Dermatitis 01/2023 - 05/2018
2	Pneumonia (Pneumonitis) 12/2022 - 01/2022
2	Thrombocytopenia (Thrombopenia) 05/2020 - 10/2014
1	Sarcoma (Soft Tissue Sarcoma) 06/2024
1	Extramammary Paget Disease (Paget Disease, Extramammary) 05/2024
1	Paronychia 01/2023
1	Exanthema (Rash) 01/2023
1	Chemical and Drug Induced Liver Injury 01/2023
1	Edema (Dropsy) 01/2023
1	Asthenia 01/2023
1	Liver Cirrhosis (Hepatic Cirrhosis) 03/2022
1	Anemia 01/2022

Drug/Important Bio-Agent (IBA)

8	Immune Checkpoint InhibitorsIBA 01/2023 - 01/2021
7	InterferonsIBA 02/2023 - 07/2011
7	Biomarkers (Surrogate Marker)IBA 01/2023 - 10/2017
6	Monoclonal AntibodiesIBA 02/2023 - 12/2014
6	Temozolomide (Temodar)FDA LinkGeneric 01/2023 - 08/2013
5	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 03/2024 - 01/2018
5	pembrolizumabIBA 01/2024 - 04/2017
5	Everolimus FDA Link 05/2020 - 02/2012
5	Imatinib Mesylate (Gleevec)FDA Link 03/2019 - 07/2011
4	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 06/2024 - 08/2018
4	dabrafenibIBA 05/2024 - 01/2020
4	trametinibIBA 05/2024 - 01/2020
4	apatinibIBA 01/2023 - 10/2018
4	camrelizumabIBA 01/2023 - 01/2020
4	Phosphotransferases (Kinase)IBA 11/2022 - 01/2012
4	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 10/2021 - 05/2014
4	palbociclibIBA 01/2021 - 11/2017
4	Sorafenib (BAY 43-9006)FDA Link 01/2018 - 11/2012
4	Tyrosine Kinase InhibitorsIBA 09/2014 - 07/2011
3	phosphatidyl-N-monomethylaminoethanolIBA 05/2024 - 01/2019
3	Programmed Cell Death 1 ReceptorIBA 08/2023 - 01/2020
3	Messenger RNA (mRNA)IBA 01/2022 - 12/2021
3	RNA (Ribonucleic Acid)IBA 01/2022 - 11/2019
3	Axitinib (AG 013736)IBA 01/2022 - 11/2019
3	Arsenic Trioxide (Trisenox)FDA Link 01/2019 - 06/2014
3	Cisplatin (Platino)FDA LinkGeneric 01/2018 - 11/2012
3	DNA (Deoxyribonucleic Acid)IBA 11/2017 - 01/2012
3	Sunitinib (Sutent)FDA Link 05/2016 - 10/2014
3	glabridinIBA 05/2016 - 01/2014
2	Immunoconjugates (Immunoconjugate)IBA 05/2024 - 01/2021
2	Epidermal Growth Factor (EGF)IBA 01/2024 - 01/2019
2	Immunoglobulins (Immunoglobulin)IBA 02/2023 - 11/2019
2	LigandsIBA 01/2023 - 09/2014
2	Bevacizumab (Avastin)FDA Link 11/2022 - 10/2021
2	AntibodiesIBA 10/2022 - 05/2022
2	Immunoglobulin G (IgG)IBA 05/2022 - 01/2022
2	toripalimabIBA 01/2022 - 11/2019
2	IpilimumabIBA 01/2022 - 04/2017
2	Adenylyl Cyclases (Adenylyl Cyclase)IBA 01/2022 - 01/2019
2	Paclitaxel (Taxol)FDA LinkGeneric 10/2021 - 05/2019
2	B7-H1 AntigenIBA 01/2021 - 11/2019
2	Cyclin-Dependent Kinase 4IBA 01/2021 - 12/2018
2	MicroRNAs (MicroRNA)IBA 05/2019 - 01/2019
2	Telomerase (Telomerase Reverse Transcriptase)IBA 01/2018 - 10/2017
2	MTOR InhibitorsIBA 01/2018 - 01/2017
2	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 01/2018 - 09/2017
2	Mitogen-Activated Protein KinasesIBA 09/2014 - 09/2014
2	Dacarbazine (DIC)FDA LinkGeneric 07/2013 - 08/2008
1	disitamab vedotinIBA 05/2024
1	hydrogen sulfite (bisulfite)IBA 05/2024
1	ErbB Receptors (EGF Receptor)IBA 01/2024
1	Extracellular Matrix ProteinsIBA 12/2023
1	Matrix Metalloproteinases (MMPs)IBA 12/2023
1	anlotinibIBA 08/2023
1	Transaminases (Aminotransferases)IBA 01/2023
1	Creatine Kinase (Creatine Phosphokinase)IBA 01/2023
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 01/2023
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2023
1	Alanine Transaminase (SGPT)IBA 01/2023
1	Myosin Type IIIBA 11/2022
1	atezolizumabIBA 11/2022
1	larotrectinibIBA 11/2022
1	tyrosine receptor (receptor, tyrosine)IBA 11/2022
1	entrectinibIBA 11/2022
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2022
1	NivolumabIBA 01/2022

Therapy/Procedure

53	Therapeutics 06/2024 - 03/2013
23	Immunotherapy 03/2024 - 09/2014
11	Drug Therapy (Chemotherapy) 02/2023 - 08/2008
2	Adjuvant Radiotherapy 06/2024 - 03/2024
2	Molecular Targeted Therapy 11/2023 - 03/2013
2	Oncolytic Virotherapy 01/2022 - 01/2020
2	Injections 01/2022 - 01/2018
1	Radiotherapy 03/2024
1	Lenses 03/2022
1	Adjuvant Chemotherapy 01/2022